ALPMY News and Press, Astellas Pharma Inc. ADR From 05/09/23

2023-05-09 08:56:49 ET Leading drugmakers are prepping for a legal fight against recently implemented U.S. drug pricing reforms which bring negotiating power to Medicare for the first time ever, Reuters reported Tuesday, citing industry sources. In March, the Centers for Medicare &a...

2023-05-04 12:20:49 ET Summary Apellis Pharmaceuticals, a commercial-stage biopharmaceutical company, is making significant strides with Syfovre, the first and only FDA-approved treatment for geographic atrophy (GA), a condition affecting millions globally. The company's strong fi...

2023-05-01 16:28:20 ET With earnings season in full swing, biotechnology stocks were volatile today. Apellis Pharmaceuticals' (NASDAQ: APLS) stock, for instance, dipped by as much as 8.5% in early-morning trading Monday before rallying in the afternoon session. Apellis' shar...

Astellas Enters into Definitive Agreement to Acquire Iveric Bio PR Newswire -Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023 - ...

2023-04-29 11:32:07 ET Astellas Pharma Inc. (ALPMF) Q4 2022 Results Conference Call April 27, 2023 03:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Naoki Okamura - Representative Director, President and CEO Yoshitsugu Shit...

2023-04-24 08:39:37 ET For further details see: Lantheus, POINT Biopharma receive FDA Fast Track status for prostate cancer candidate

2023-04-19 06:39:26 ET Summary Biotechnology is the second worst performer in healthcare, significantly lagging behind the US market year-to-date. However, there could now be opportunities to get a bargain in the biotechs. Kura Oncology may be of interest to investors as this US b...

Results from Astellas' Phase 3 SPOTLIGHT Trial of Investigational Zolbetuximab Published in The Lancet PR Newswire TOKYO , April 14, 2023 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") today announced that Th...

2023-04-12 04:33:45 ET Astellas Pharma ( OTCPK:ALPMY ) ( OTCPK:ALPMF ) and the Center for iPS Cell Research and Application (CiRA), Kyoto University entered the second phase of a joint research agreement to promote the use of differentiated cells and tissues derived from human ind...

CiRA, Kyoto University and Astellas Second Phase Joint Research Agreement Signed for Medical Applications of iPS Cells PR Newswire KYOTO, Japan and TOKYO , April 11, 2023 /PRNewswire/ -- The Center for iPS Cell Research and Application, Kyoto University (...